SA
Go ProLog In
PRME
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Buy
9 analysts·Limited coverage
64
Score
5 Buy (56%)4 Hold (44%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
556%
Hold
444%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$12.00
+309.6%
Consensus
$17.00
+480.2%
Bull
$23.00
+685.0%
12-Month Target Range9 analysts
$12.00$17.00$23.00
Current $2.93Consensus
Current Price
$2.93
Upside to Consensus
$14.07

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+74.14%
EPS—
FY2028
Rev+39.04%
EPS—
FY2029
Rev-41.37%
EPS—

Earnings Surprises

Recent Analyst Actions

May 7, 2024Jefferies
Prime Medicine assumed with a Buy at Jefferies
Target:$15.00
+177.8%from $5.40
Apr 2, 2024Wedbush
Prime Medicine initiated with a Buy at Wedbush
Target:$12.00
+89.9%from $6.32
Oct 9, 2023BMO Capital
Preclinical-Phase Firm Prime Medicine's Gene Editing Platform Has Potential: Analyst
Target:$19.00
+117.1%from $8.75
Nov 14, 2022Morgan Stanley
Morgan Stanley Initiates Coverage On Prime Medicine with Equal-Weight Rating, Announces Price Target of $23
Target:$23.00
+8.9%from $21.12

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance